Impurezas de nitrosaminas em medicamentos: um panorama geral
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora - Campus Avançado de Governador Valadares
DOI
Abstract
In 2018, medicines containing valsartan were reviewed due to contamination by
an impurity called NDMA, which belongs to the class of nitrosamines known for their
carcinogenic potential. This study aims to understand the risks associated with the
presence of nitrosamines in medications, including their chemical and toxicological
aspects. A documentary analysis was conducted on regulatory authority websites and
scientific databases. The presence of impurities in medications affects their safety,
quality, and efficacy. In order to harmonize regulations and promote a global standard
of quality, the ICH was established in 1990, and since then, several guidelines for the
evaluation and control of impurities have been developed. Nitrosamines are highly
potent mutagenic impurities and are described as part of the "concern group" in the
ICH M7 guideline. Due to their mutagenic potential, the TTC limits are not applicable
to compounds belonging to this group. An in vitro mutagenicity test, the bacterial
reverse mutation test, may be necessary to determine the mutagenic potential and the
control strategy to be adopted for these compounds. Nitrosamines are a class of
compounds characterized by a nitroso group linked to an amino functional group. Their
genotoxicity depends on metabolic activation, which occurs via alpha-hydroxylation by
cytochrome P450-dependent enzymes, generating highly reactive carbocations or
diazonium compounds capable of alkylating cellular macromolecules such as DNA,
RNA, and chromosomes. Nitrosamines are formed through a N-N bond known as Nnitrosation, where a nitroso functional group is introduced into a molecule containing
NH (e.g., amines) by a nitrosating agent under specific reaction conditions. The
formation of nitrosamines can occur from various sources, such as during the synthesis
of the active pharmaceutical ingredient (e.g., valsartan), drug-excipient interactions
(e.g., metformin), or due to drug instability (e.g., ranitidine). Therefore, a detailed risk
assessment is necessary, considering the entire process from the synthesis of the
active pharmaceutical ingredient to the production of the finished product, in order to
establish acceptable limits and develop control strategies for these impurities, which
represent a public health issue.
Description
Keywords
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

